MC
AKTS

Merck & Co’s Aktis Oncology AKTS Stock Holding History

Merck & Co’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17M Buy
+952,844
New +$18.5M 4.88% 6

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Merck & Co's AKTS Position: Q1 2026 in Review

Merck & Co opened a new position in Aktis Oncology (AKTS) in Q1 2026: 952,844 shares worth $17M. The stake represents 4.88% of the portfolio and ranks #6 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

  • Merck & Co held 952,844 shares of Aktis Oncology worth $17M as of Q1 2026.
  • Aktis Oncology was a new Merck & Co position in Q1 2026.
  • Aktis Oncology made up 4.88% of Merck & Co's portfolio in Q1 2026, its #6 holding.
  • 69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.